Johnson&Johnson COVID-19 Vaccine
South Africa Halts Johnson & Johnson COVID-19 Vaccine Rollout
South African Health Minister, Zweli Mkhize has announced that the country would temporarily halt its Johnson & Johnson COVID-19 vaccine rollout. This follows the Food and Drug Administration’s (FDA) temporary suspension of the vaccine in the United States after six recipients developed a rare blood-clotting disorder. According to The New York Times, all six recipients were women aged between 18 and 48, and each of them developed the illness within one to three weeks of vaccination. “We are recommending a pause in the use of this vaccine out of an abundance of caution,” says Dr Peter Marks, FDA Director for Biologics Evaluation and Research. As it stands, no South African recipients have reported experiencing blood clots following the vaccine. However, Mkhize says that they will ...
AstraZeneca Vaccine Only ‘Minimally Effective’ Against South African COVID-19 Variant, says Researchers
Image sourced from TimesLIVE The AstraZeneca COVID-19 vaccine has proven ‘minimally effective’ against the South African variant, according to the Wits Vaccines and Infectious Diseases Analytics (VIDA) research unit. So far, South Africa has received one million doses of the Oxford/AstraZeneca vaccine. In an official report, researchers from South Africa and the UK found that “viral neutralisation by sera induced by the ChAdOx1 nCoV-19 coronavirus vaccine against the B.1.351 coronavirus variant were substantially reduced when compared with the ‘original’ strain of the coronavirus”. /* custom css */ .tdi_3_ec0.td-a-rec-img{ text-align: left; }.tdi_3_ec0.td-a-rec-img img{ margin: 0 auto 0 0; } Professor of Vaccinology at the University of Oxford, Sarah Gilbert revealed that efforts are alrea...
